Brain Penetrable Histone Deacetylase 6 Inhibitor SW-100 Ameliorates Memory and Learning Impairments in a Mouse Model of Fragile X Syndrome

Alan P. Kozikowski^{1, *}, Sida Shen^{2,‡}, Marta Pardo^{3,‡}, Maurício T. Tavares², Dora Szarics⁴, Veronick

Benoy⁵, Chad A. Zimprich⁶, Zsófia Kutil,⁷ Guiping Zhang², Cyril Bařinka,⁷ Matthew B. Robers⁶, Ludo Van

Den Bosch⁵, James H. Eubanks⁴, & Richard S. Jope³

¹ StarWise Therapeutics LLC, Madison, WI 53719, United States

² Department of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, University of Illinois at Chicago, Chicago, IL 60612, United States

³ Department of Psychiatry and Behavioral Sciences, Miller School of Medicine, University of Miami, Miami, FL 33136, United States

⁴Division of Genetics and Development, Krembil Research Institute, University Health Network, Toronto, Ontario M5G 2C4, Canada

⁵ Laboratory of Neurobiology, Center for Brain & Disease (VIB) and Leuven Brain Institute (LBI), KU Leuven, B-3000 Leuven, Belgium

⁶ Promega Corporation, Madison, WI 53711, United States

⁷ Laboratory of Structural Biology, Institute of Biotechnology of the Czech Academy of Sciences, Prumyslova 595, 252 50 Vestec, Czech Republic

[‡]S.S and M.P. contributed equally to this paper.

*Corresponding author: Alan P. Kozikowski, E-mail: akozikowski@starwisetrx.com

Supplementary tables and figures.

Compound	MW	clogP	clogD (7.4)	<i>p</i> K _a (basic)	tPSA	HBD	CNS MPO ^b
6	217.23 (1)	0.97 (1)	0.97 (1)	3.46 (1)	64.93 (1)	2 (0.5)	5.50
7	270.33 (1)	3.02 (0.995)	3.01 (0.495)	5.12 (1)	52.57 (1)	2 (0.5)	4.99
8	299.31 (1)	2.32 (1)	2.30 (0.85)	5.95 (1)	64.93 (1)	2 (0.5)	5.35
9	299.31 (1)	2.32 (1)	2.30 (0.85)	5.86(1)	64.93 (1)	2 (0.5)	5.35
10	302.76 (1)	3.30 (0.85)	3.29 (0.355)	0.99 (1)	52.57 (1)	2 (0.5)	4.71
11	286.31 (1)	2.84 (1)	2.83 (0.585)	0.84 (1)	52.57 (1)	2 (0.5)	5.09
12	296.33 (1)	2.21 (1)	2.15 (0.925)	6.55 (1)	76.96 (1)	3 (0.1)	4.19
SW-100	316.78 (1)	3.74 (0.63)	3.73 (0.135)	2.91 (1)	52.57 (1)	2 (0.5)	4.27
TubA	335.41 (1)	2.54 (1)	2.34 (0.83)	7.14 (1)	55.81 (1)	2 (0.5)	5.33

Table S1. Physicochemical properties of analogs 6-12, SW-100, and TubA^a

^aAll the values were obtained by MarvinSketch version 18.5. ^bCNS MPO values were calculated according to the equation in the article by Wager, T. T. et al., *ACS Chem. Neurosci.* **2016**, *7*, 767-775.

Table S2. Brain/plasma pilot PK studies of TubA.^a

route	dose (mg/kg)	time (h)	brain concentration (ng/mL)	plasma concentration (ng/mL)	brain/plasma ratio
IV	3	0.133	40.5 ± 3.4	273.5 ± 30.4	0.15
IV	3	1	17.5 ± 2.6	20.3 ± 0.64	0.86

^aTubA was administered to C57BL/6 male mice by IV administration at the dose of 3 mg/kg. Blood and brain samples were collected at 8 min and 60 min time-points. Brain tissues were homogenized at a 1:4 ratio of tissue weight (g) to volume of PBS (mL). The data found (ng/mL) was multiplied by 5 to obtain the concentration (ng/mL) in brain tissues. PK studies were performed by Pharmaron, Inc. (Irvine, CA).



Figure S1. The comparison of pK_a values (basic and acidic) and P-gp efflux ratios.





¹H NMR spectra and LC-MS purity reports for compounds 6-12, SW-100, TubA, and NexA









Nexturastat A

